Has Katherine Moxley, MD received payments from drug or device companies?

Yes. Drug and device makers reported $44,211 in general payments to Katherine Moxley, MD across 71 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Katherine Moxley, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Katherine Moxley, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Katherine Moxley, MD

Gynecologic Oncology · Tulsa, OKNPI 1548308448

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (38.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by GSK at 46.6% of the total. 2025 is the largest year on record at $24,300, 3.2 times the $7,613 reported in 2019. Among gynecologic oncology clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$44,211in general payments, 2019–2025

Across 71 payments — averaging $622.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$21K
Intuitive Surgical$8K
Tesaro, Inc.$8K
AstraZeneca$6K
AVEO Pharmaceuticals, Inc.$1K
AbbVie$859
plus $292 from 7 others

$376,011in research payments, 2019–2025

Across 76 payments — averaging $4947.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$246K
Takeda Pharmaceuticals U.S.A., Inc.$124K
Incyte Corporation$2K
E.r. Squibb & Sons, L.L.C.$2K
Pfizer$1K
F. Hoffmann-la Roche AG$619

What the payments were for

Consulting fees$16,85038%
Speaking & faculty fees$16,12536%
Travel & lodging$5,40712%
Food & beverage$1,2353%
Education$4,59310%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	18	$20,587
Intuitive Surgical	26	$8,445
Tesaro, Inc.	7	$7,519
AstraZeneca	3	$5,509
AVEO Pharmaceuticals, Inc.	1	$1,000
AbbVie	3	$859
Clovis Oncology, Inc.	4	$93
Daiichi Sankyo Inc.	3	$62
Seagen Inc.	1	$43
Novartis	2	$37
Regeneron Healthcare Solutions, Inc.	1	$19
Eisai Inc.	1	$19
Takeda Pharmaceuticals U.S.A., Inc.	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ZEJULA$16,064
JEMPERLI$11,718
DAVINCI XI$4,500
Da Vinci Surgical System$3,672
Enhertu$3,425
FOTIVDA$1,000
Elahere$840

How this compares

$44,211 in reported general payments places this provider in the 90th percentile of 21 gynecologic oncology providers in Oklahoma.

See all gynecologic oncology providers in Oklahoma →

Medicare billing

Part B allowed, 2024

$1,931,110

Medicare patients

413

Services billed

87,764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	19	$12,705
Estradiol	43	$1,973
Megestrol Acetate	22	$1,020
Ondansetron Hcl	38	$531
Prochlorperazine Maleate	39	$412
Letrozole	19	$401
Oxycodone Hcl	41	$325
Lidocaine-PrilocaineLidocaine/Prilocaine	21	$235
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	18	$231
Nystatin	15	$217
Celecoxib	14	$154
Levofloxacin	27	$142
Ondansetron OdtOndansetron	14	$122
Methocarbamol	12	$94
Fluconazole	14	$74

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in Tulsa

Daron StreetTulsa$55K
Michael GoldTulsa$15K
Alfred JenkinsTulsa$994
Debra RichardsonOklahoma City$97K
Camille JacksonOklahoma City$35K
Tara CastellanoOklahoma City$26K
Joan WalkerOklahoma City$11K
Christina WashingtonOklahoma City$9K
Roger PfeifferOwasso$7K
Elizabeth EvansOklahoma City$3K

See the full list for Oklahoma →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →